Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study
- 15 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 35 (5), 1418-1427
- https://doi.org/10.1038/s41375-021-01141-4
Abstract
Carfilzomib (CFZ) improves survival in relapsed/refractory multiple myeloma but is associated with cardiovascular adverse events (CVAEs). We prospectively investigated the effect of CFZ on endothelial function and associations with CVAEs. Forty-eight patients treated with Kd (CFZ 20/56 mg/m2 and dexamethasone) underwent serial endothelial function evaluation, using brachial artery flow-mediated dilatation (FMD) and 26S proteasome activity (PrA) measurement in PBMCs; patients were followed until disease progression or cycle 6 for a median of 10 months. FMD and PrA decreased acutely after the first dose (p < 0.01) and FMD decreased at cycles 3 and 6 compared to baseline (p ≤ 0.05). FMD changes were associated with CFZ-induced PrA changes (p < 0.05) and lower PrA recovery during first cycle was associated with more prominent FMD decrease (p = 0.034 for group interaction). During treatment, 25 patients developed Grade ≥3 CVAEs. Low baseline FMD (HR 2.57 lowest vs. higher tertiles, 95% CI 1.081–6.1) was an independent predictor of CVAEs. During treatment, an acute FMD decrease >40% at the end of first cycle was also independently associated with CVAEs (HR = 3.91, 95% CI 1.29–11.83). Kd treatment impairs endothelial function which is associated with PrA inhibition and recovery. Both pre- and posttreatment FMD predicted CFZ-related CVAEs supporting its role as a possible cardiovascular toxicity biomarker.Keywords
This publication has 56 references indexed in Scilit:
- Differential regulation of proteasome functionality in reproductive vs. somatic tissues of Drosophila during aging or oxidative stressThe FASEB Journal, 2013
- Assessment of atherosclerosis: the role of flow-mediated dilatationEuropean Heart Journal, 2010
- Proteasome inhibition prevents experimentally-induced endothelial dysfunctionLife Sciences, 2009
- Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomaBlood, 2007
- Interrelated modulation of endothelial function in Behcet's disease by clinical activity and corticosteroid treatmentArthritis Research & Therapy, 2007
- Endothelial function and dysfunction. Part IJournal Of Hypertension, 2005
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003
- Inhibition of Proteasome Activity Induces Concerted Expression of Proteasome Genes and de Novo Formation of Mammalian ProteasomesJournal of Biological Chemistry, 2003
- Endothelial functionThe American Journal of Cardiology, 2002
- Automated Ultrasonic Measurement of Human Arteries for the Determination of Endothelial FunctionUltraschall in der Medizin - European Journal of Ultrasound, 2000